Trius Gets $29.5M Defense Contract
Bruce V. Bigelow5/20/10
The Defense Threat Reduction Agency has awarded a contract that could be worth as much as $29.5 million through 2015 to San Diego’s Trius Therapeutics to develop novel antibiotics for gram-negative bacterial pathogens. In a statement, Trius says it will use its proprietary Focused Antisense Screening Technology and expertise in structure-based drug design to optimize promising antibacterial compounds for a variety of microbes, including germs that cause Bubonic plague, rabbit fever (tularemia), and Melioidosis.
